Cyclacel Pharmaceuticals announced that Brian Schwartz, M.D. will assume the role of interim Chief Medical Officer, CMO, of the Company effective immediately. Dr. Schwartz will succeed Mark Kirschbaum, M.D., whose employment was terminated by the Company. Dr. Schwartz has served as a member of the board of directors of the Company since December 2020.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CYCC:
- Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
- Cyclacel Pharmaceuticals files to sell 411,969 shares of common stock for holder
- Biotech Alert: Searches spiking for these stocks today
- Cyclacel Pharmaceuticals regains compliance with Nasdaq minimum bid price rule
- Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
